Clinical Trial Detail

NCT ID NCT01927341
Title Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

Therapies

Binimetinib

Panitumumab

Age Groups: adult

No variant requirements are available.